Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK3 | Q9Y2K2 | 11/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 9/20 | 1.00 |
| ▸ | PAK1 | Q13153 | 8/20 | 0.85 |
| ▸ | STK26 | Q9P289 | 6/20 | 0.85 |
| ▸ | SIK1 | P57059 | 4/20 | 0.85 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.85 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.85 |
| ▸ | PAK3 | O75914 | 1/20 | 0.85 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.85 |
| ▸ | TEK | Q02763 | 1/20 | 0.85 |
| ▸ | MELK | Q14680 | 1/20 | 0.85 |
| ▸ | PKN3 | Q6P5Z2 | 1/20 | 0.85 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.85 |
| ▸ | STK3 | Q13188 | 5/20 | 0.75 |
| ▸ | STK24 | Q9Y6E0 | 5/20 | 0.75 |
| ▸ | STK4 | Q13043 | 4/20 | 0.75 |
| ▸ | STK25 | O00506 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16415445 | 1.00 | SIK3 (1.00) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16419541 | 0.91 | SIK3 (0.83) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16421423 | 0.86 | SIK2 (1.00) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16414861 | 0.86 | SIK2 (1.00) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL26074242 | 0.86 | SIK2 (1.00) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16414665 | 0.84 | PAK1 (0.86) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16421442 | 0.84 | PAK1 (0.86) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16414690 | 0.84 | SIK3 (0.77) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16421432 | 0.84 | SIK3 (0.77) | SIK3SIK2PAK1STK26SIK1 | |
| SCHEMBL16414924 | 0.81 | PAK1 (0.75) | SIK3SIK2PAK1STK26SIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | SIK3 149/4885SIK2 56/4885PAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.